

https://dspace.org/

Who pays and what pays off in sexual and reproductive health A review of the cost and costeffectiveness of interventions and implications for future funding and markets

Gesine Meyer-Rath; Lise Jamieson; E Mudimu; Katherine Snyman; J Ong ...

ELSEVIER SCIENCE INC
https://hdl.handle.net/10539/48517
WOS

Downloaded from a DSpace repository. https://dspace.org/

Innovations in Sexual and Reproductive Health 4

Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets

Gesine Meyer-Rath, Lise Jamieson*, Edinah Mudimu, Katherine Snyman, Jason J Ong, Joseph Corlis, Mitchell Warren, Virginia Wiseman, Katharine Kripke, Ruanne Barnabas, Andrew Phillips, Jennifer Head, Karin Stenberg, Elizabeth A Sully*

Lancet 2025; 406: 2152–67

This is the fourth in a **Series** of five papers about innovations in sexual and reproductive health. All papers in the Series are available at thelancet.com/series/sexual-reproductive-health

See **Comment** page 2038

*Contributed equally

Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (Prof G Meyer-Rath PhD MD, L Jamieson PhD); **Department of Global Health, School of Public Health, Boston University, Boston, MA, USA** (Prof G Meyer-Rath); **South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa** (Prof G Meyer-Rath, L Jamieson); **Department of Decision Sciences, University of South Africa, Pretoria, South Africa** (E Mudimu PhD); **London School of Hygiene and Tropical Medicine, London, UK** (K Snyman MSc, Prof J J Ong PhD, Prof V Wiseman PhD); **Monash University, Melbourne, VIC, Australia** (Prof J J Ong); **Avenir Health, Glastonbury, CT, USA** (J Corlis DrPH, K Kripke PhD); **Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA** (J Corlis); **AVAC, New York, NY, USA** (M Warren BA); **The Kirby Institute, University of New South Wales, Sydney, NSW, Australia** (Prof V Wiseman); **Division of Infectious Diseases, Massachusetts General Hospital, Harvard School of**

This Series paper provides a summary of what is known about the funding, cost, and cost-effectiveness of sexual and reproductive health and rights interventions, interrogates the likely impacts of increasing or reducing future sexual and reproductive health and rights funding, and provides recommendations for policy and regulatory changes from an economic perspective. Interventions that target HIV and sexually transmitted infections, contraceptive interventions, and abortion care are among the most cost-effective health interventions worldwide, but their funding is under severe duress. In 2023, approximately US$35 billion was spent on these intervention areas across low-income and middle-income countries—only two-thirds of the $52 billion needed per year. HIV treatment and prevention, as well as contraceptive commodities, rely heavily on donor funding, which has decreased since 2017. The discontinuation of the US Agency for International Development funding in early 2025, in particular, requires that the most impacted countries will have to do more with much less going forward.

Introduction

Funding for sexual and reproductive health and rights (SRHR) services is under severe duress across the globe, even before US cuts to foreign aid for health in early 2025, which had been contributing approximately 26% of all outside assistance to health programmes in low-income and middle-income countries (LMICs). In this Series paper, we summarise what is known about the funding for and the cost and cost-effectiveness of SRHR interventions, based on a review of the literature to identify evidence gaps and factors that improve efficiency and sustainability (for a full definition of the term SRHR see the results of the Guttmacher–*Lancet* Commission).[1] The Guttmacher–*Lancet* Commission[1] recommended an essential package of SRHR services and information that includes contraceptive services, maternal and newborn care, prevention and treatment of HIV, and care for other sexually transmitted infections (STIs), as well as comprehensive sexuality education; safe abortion care; prevention, detection, and counselling for gender-based violence; prevention, detection, and treatment of infertility and cervical cancer; and counselling and care for sexual health and wellbeing.[1] For this Series paper, we conducted a more in-depth review of interventions for HIV and STIs, and a shorter review of other aspects of the essential package of SRHR services, including contraception and abortion care (our analysis excludes maternal and newborn health interventions beyond HIV treatment for the elimination of vertical transmission, as in the past these were often covered by other funding mechanisms). Lastly, we also interrogated the likely impacts of increasing or reducing future funding for these areas and end with recommendations for changes to the policy and regulatory landscape that would render services more efficient, cost-effective, and financially sustainable.

Current funding landscape: global estimates

In order to estimate the combined global funding needed for HIV and STI screening, prevention and management, contraceptive care, and abortion care, we combine global estimates for each of these intervention areas generated using different methods. This provides a rough estimate of approximately US$52 billion needed per year across LMICs in 2023, of which only two thirds (approximately $35 billion) is currently available—the majority of which ($20 billion or 56%) is spent on HIV care (figure 1). The methods behind these estimates are explained in more detail below.

Funding for HIV care

In early 2025, the US President's Emergency Plan for AIDS Relief (PEPFAR), which provided more than 26% of global HIV funding in 2022, had both its budget[2] (which was already in decline for the last 3 years[3]) and its reach curtailed through the current US administration's dismantling of the US Agency for International Development, which had been responsible for implementing 60% of PEPFAR programmes.[4] This defunding follows a continuous decrease in HIV funding from a high of $24 billion (costs from 2019) in 2017.[3] Before the reduction of the PEPFAR budget, global HIV funding in 2023 was nearly $20 billion, already a 17% decrease from the peak in 2017, and approximately a third off the projected $29 billion required for the global HIV response—a shortage that is set to increase in the

following years.[3] Although approximately 60% of resources in 2023 were funded from the domestic budgets of LMICs with high HIV prevalence, these countries' fiscal space continues to be constrained by the aftermath of the COVID-19 pandemic, debt servicing, and conflict and other humanitarian crises.[3] Concurrently, the mobilisation of donor funding for HIV prevention, care, and treatment specifically and SRHR more generally has become increasingly difficult.

Funding for STI care

Current funding for STI prevention, care, and treatment is not tracked as well as the funding for HIV care, as nearly all is funded from countries' own health budgets.[5] A 2017 analysis of WHO's 2022–30 global health sector strategies on HIV, viral hepatitis, and STIs included an estimation of the cost of STI care, including human papillomavirus (HPV) vaccination, across 118 LMICs.[5] The analysis estimated that annual costs would increase from $3·4 billion in 2023 to $6·3 billion by 2026 when fully scaled up, but could decline thereafter owing to unspecified efficiency gains.[5] This includes $344 million by 2030 for primary prevention, and $1·9 billion for outreach, screening, and management of treatment failures and antibiotic resistance.[5]

Funding for contraception and abortion care

Providing current levels of contraceptive care in LMICs costs an estimated $9·0 billion annually, which is considerably below the estimated $13·6 billion required to provide all women wanting to avoid pregnancy with modern methods (adjusting to 2023 US dollars, based on cost and coverage estimates for 2024).[6] Although domestic government funding for contraception services has remained stable since 2019, at approximately $1·7 billion, there have been notable declines in donor expenditures over that same period, similar to funding for HIV prevention, care, and treatment.[8] The most recent estimates show a 10% decline from 2021 to 2022,[2] and current cuts to overseas direct assistance budgets across Europe indicate this trend is unlikely to reverse in the coming years.

Additionally, an estimated 19·7 million women in LMICs currently require post-abortion care annually due to unsafe abortions, resulting in 20 824 maternal deaths from unsafe abortions and contributing to $2·3 billion for post-abortion care services (costs adjusted to 2023 US dollars; see the first paper[7] in this series).[6] The costs of safe abortion and post-abortion care are estimated to be $3·0 billion annually, although if all abortions were provided safely, this would drop to $1·6 billion annually, resulting in cost-savings of $1·5 billion per year (figure 1).[6]

Future funding landscape

Funding for HIV prevention, care, and treatment

Donor funding and country-level investments in SRHR services are under severe threat. Although domestic funding remains the main contributor, countries will potentially need to do more with less going forward as contributions from global donors, such as PEPFAR and The Global Fund to Fight AIDS, Tuberculosis and Malaria, have plummeted.

A number of analyses have been published estimating the impact of the complete or partial cessation of PEPFAR support for global health. Each uses one or more established health–state transition models parameterised with local epidemiological, cost, and financing data. Across analyses, the main sources of uncertainty were the size and duration of future funding reductions, the translation of decreases in funding into decreases in intervention coverage, and the amount and quality of mitigation of these impacts through domestic resource mobilisation or gains in programmatic efficiency. Stover and colleagues[9] combined results from eight models and three additional analyses to estimate the impact across the areas of HIV, tuberculosis, family planning, and maternal and child health for up to 80 countries from 2025 to 2040. A complete cessation of US foreign assistance for global health would result in 15·2 (uncertainty range, 9·3–20·8) million additional AIDS-related deaths, 2·2 (1·5–1·9) million additional tuberculosis deaths, 7·9 million additional child deaths from other causes, 40–55 million additional unplanned pregnancies, and 12–16 million unsafe abortions.[9] If made permanent, these cuts to US funding would reverse decades of progress in global health and return deaths and new cases to levels last seen in the 1990s.[9] Focusing on the impact on HIV alone, Ten Brink and colleagues[10] analysed the effect of reductions in US and European foreign health funding by 2030 in 26 high-prevalence countries, estimating an additional 0·8–2·9 million deaths in this period, as well as 4·4–10·8 million new HIV infections.



Figure 1: **Indicative annual funding levels for HIV care, STI care, contraception, and abortion care**
Funding levels are indicative only and were generated using different methods and assumptions. For STI care, contraception, and abortion, the bars represent estimated current expenditure based on assumed current coverage multiplied by assumed costs. For abortion, the funding needed category includes the cost-saving impact of providing abortions safely. STI=sexually transmitted infection.

Medicine, Boston, MA, USA (Prof R Barnabas PhD)**; Institute for Global Health, University College London, London, UK** (Prof A Phillips PhD)**; Synergy Scientifics, Port Orford, OR, USA** (J Head PhD)**; World Health Organization, Geneva, Switzerland** (K Stenberg)**; Guttmacher Institute, New York, NY, USA** (E A Sully PhD)

Correspondence to:
Prof Gesine Meyer-Rath, Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
gesine@bu.edu

Funding for STI prevention, care, and treatment

The funding landscape for the control of STIs remains chronically insufficient. Global health initiatives, as well as national public health programmes, often prioritise HIV rather than a specific focus on comprehensive funding for STI care. This underfunding hampers the capacity for effective prevention, treatment, and research, including innovations, such as new diagnostic tools, vaccines, and behavioural interventions.[11] The absence of robust financial commitment also undermines efforts to integrate STI services into broader sexual and reproductive health programmes and other related services.

Funding for contraception and abortion care

The Adding It Up report by the Guttmacher Institute (included in Stover and colleagues[9]) models the impacts of current care and declining funding for contraception, in addition to the total costs necessary to meet all contraceptive needs for LMICs.[6] Providing contraceptive care to 714 million current users in LMICs is estimated to prevent 311 288 unintended pregnancies and 133 635 maternal deaths. Every $100 million decrease in funding for contraception is estimated to result in 8·1 million more unintended pregnancies and 2173 maternal deaths.[12] Given the current termination of all US grants for family planning (a total of $607·5 million), the Guttmacher Institute estimates that this will result in 47·6 million women and couples denied contraceptive care in LMICs in 2025, resulting in 17·1 million unintended pregnancies, including 5·2 million unsafe abortions, which will result in an estimated 34 000 deaths.[13]

If funding for contraception was scaled up to meet all expressed needs in LMICs, annual cost would have to increase from $1·38 to $2·09 per capita. An estimated 41% of contraceptive care expenditures were funded by international donors as of 2022,[8] and were heavily dependent on three countries: the USA (43% of all donor expenditures as of 2022), the Netherlands (16% of all donor expenditures as of 2022), and the UK (13% of all donor expenditures as of 2022), all of which have reduced overseas direct assistance funding[2] or, in the case of the USA, terminated all programmes supported by that funding. In the context of a large and growing financing gap, domestic financing for contraception and financing innovations that promote scale-up is crucial.

See Online for appendix

Finally, if safe abortion care services were scaled up to meet all needs on a global scale, such that all people having abortions in LMICs have access to safe abortion care, the costs of safe abortion care would increase from $774 million to $1·3 billion annually (when adjusted to 2023 US dollars).[6] However, by scaling up safe abortion services, the resulting decrease in complications—and therefore costs associated with post-abortion care—would result in a drop in annual unsafe abortion-related maternal deaths from 21 138 globally to as few as 1145.[6]

The economic impact of defunding SRHR

Even before the change in US policy regarding foreign aid, the economic consequences of missing the 95–95–95 targets by 2030 had been estimated to be $14 billion globally between 2021 and 2050, using a full-income approach (ie, combining economic gains from improved productivity or economic growth plus health gains).[14] However, if targets were met, the return on investment would be $11–14 for every dollar spent, with the highest returns in low-income countries.[14] The impact of scaling up STI services to achieve a 90% reduction in curable STIs has been estimated as part of the analysis of WHO's global STI strategy,[5] which noted potential returns on the $18 million investment in terms of health-care cost-savings and productivity gains, in particular from a reduction in cervical cancer by 70%. Additionally, the authors projected reductions in health-care costs and productivity losses from STIs and morbidity and mortality owing to infertility, pregnancy and congenital complications, and psychosocial impacts. However, the total value of these economic gains was not estimated.[5]

What do we know about the cost-effectiveness of SRHR interventions?

In order to summarise what is known about the funding, cost, and cost-effectiveness of SRHR interventions (see panel 1 for definitions), we conducted a review of the literature on cost analyses and economic evaluations of HIV and STI interventions and contraception and abortion care between January, 2009, and September, 2024, using PubMed as well as additional publications, reports, and grey literature recommended by coauthors who are experts in their respective fields.[15] We extracted the main findings of existing systematic and non-systematic literature reviews and added publications not yet included in other reviews. We summarise the main findings by disease and intervention area. Results and thresholds values are given as reported in the papers (ie, unadjusted over time; more detailed findings are summarised in the appendix pp 11–36). The detailed search strategy can be found in the appendix (p 3), and a short overview of evidence gaps can also be found in the appendix (p 7).

Comparisons of SHRH interventions

Few economic analyses have compared interventions across the entire spectrum of SRHR interventions incorporated here. In addition to interventions reviewed in detail below, a scoping review of SRHR interventions found the following interventions to be cost-effective under a variety of thresholds: school-based and internet-based sexuality and sexual health education programmes for adolescents; community mobilisation programmes; an intervention combining microfinance with gender and HIV training for the prevention of intimate partner violence and violence against female sex workers; a parenting programme for preventing abuse of adolescents by their caregivers; cervical cancer treatment

including lesion removal, radiotherapy, chemotherapy, and radical hysterectomy with pelvic lymph node dissection; clinical examination for early detection as well as lumpectomy, radiotherapy, mastectomy, and adjuvant treatment with oophorectomy and tamoxifen after mastectomy; and population-based screening for prostate cancer.[16] The following interventions were found not to be cost-effective: infertility services including intrauterine insemination and in vitro fertilisation and neoadjuvant chemotherapy for advanced ovarian cancer. Interventions such as mammography screening and different chemotherapy regimens for breast cancer had variable results.[16] Although there are crucial gaps in economic analyses of many domains of SRHR interventions, there is clear evidence that a large set of SRHR services are indeed cost-effective interventions.[16]

One meta-regression compared the cost-effectiveness of select interventions for HIV, malaria, syphilis, and tuberculosis in 128 countries based on 144 existing analyses that reported cost per disability-adjusted life-year (DALY) averted.[17] The analysis predicted incremental cost-effectiveness ratios (ICERs) for antenatal syphilis screening, antiretroviral therapy (ART) for children and adults, and pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) and female sex workers, in addition to several tuberculosis and malaria interventions. The study found that antenatal syphilis screening was the most cost-effective of these interventions across regions, whereas PrEP for MSM was the least cost-effective.[17] Within HIV, multiple allocative efficiency modelling exercises have compared a wide range of interventions in different settings, including the HIV Investment Case that is run annually for South Africa to optimise the allocation of financial resources for HIV.[18] Across 11 annual iterations of this Investment Case, the most cost-effective and the only cost-saving intervention was increasing condom provision and uptake, as it averts treatment costs far outweighing the costs of condom provision itself. Additionally, further expansions of testing coverage across different populations and of ART eligibility, uptake, and retention were shown to be cost-effective and affordable under the relevant HIV budget in each iteration.[19]

HIV

ART

13 systematic and 11 non-systematic reviews summarised 353 individual papers on ART (there was some overlap between the papers included in each review, which this metric does not account for). The results suggested that scaling up ART was cost-effective under a 1×gross domestic product per capita per DALY averted threshold.[20] ART provision cost was reduced, and its cost-effectiveness improved, by improving service efficiency through differentiated service delivery (DSD) based on clients' need (ie, DSD models),[21] including community-based delivery and home-based care[22,23] and task shifting from doctors to nurses.[24–26] Notably, community ART delivery was found to be no more expensive than facility-based ART delivery, as the costs of home visits tended to be offset by savings from reduced health service use.[27] DSD decreased costs for both the patient and the provider, despite increased start-up costs.[28] In addition, economic strengthening interventions in DSD,[29] newer first-line treatment options,[30] interventions for improving adherence using peer health workers,[31] SMS or smartphone-based interventions,[32,33] and promoting water, sanitation, and hygiene interventions to prevent water-borne diseases in people on ART[34] were all found to be cost-effective, albeit under different thresholds.

Panel 1: **What does cost-effectiveness measure?**

Traditionally, economic evaluations, including modelled cost-effectiveness analyses, are used to inform health intervention prioritisation under resource constraints, with clinical guidelines, targets, and budgets developed once a decision to introduce an intervention has been made. Cost-effectiveness analyses compare the outcome of an intervention—such as additional survival, infections averted, or couple-years protected from pregnancy—to its cost. An incremental cost-effectiveness ratio (ICER) is calculated by dividing the difference in total costs by the difference in the chosen health outcome or effect. This ICER is then compared with a cost-effectiveness threshold defined by different methods, including a country's productivity (eg, gross domestic product per capita) per disability-adjusted life-year averted; the historic relationship between health expenditure and increases in life expectancy (opportunity cost approach); and another approximation of a funder's willingness to pay, or the ICER of an existing, already funded intervention.

The cost of health interventions is driven by factors such as disease prevalence and incidence, the size and type of subpopulations, the ease with which subpopulations can be identified and reached, the success of risk targeting, the model of care and staff cadre used in its implementation, whether the intervention is feasible and acceptable to scale up, and whether implementation happens in a disease-specific silo or is integrated into other care (figure 1). As a result, many of the results summarised in this paper will likely change due to the defunding of HIV and other sexual and reproductive health programmes. Additionally, effectiveness—and cost-effectiveness—depends on an intervention's ability to control or eliminate a disease, with ICERs increasing as elimination requires service provision to harder to reach populations (appendix p 1). Of central importance in the process of economic evaluation is how cost-effectiveness is defined and how outcomes are calculated (appendix p 2).

In addition, 63 papers not included in the reviews confirmed the aforementioned findings, with analyses showing the cost-saving aspect of task shifting and DSD.[35–39] DSD exhibited excellent outcomes at a similar cost in Uganda,[40] was costlier in Zambia (partly explained by increased resource use from increased retention),[41] and was cost-effective in high-prevalence settings in South Africa.[42] Further, in both facility-based and DSD models, cost-savings could be generated by initiating treatment earlier in adults and children[43–46] (as early as the same day that a positive HIV test result is received[47]) and by dispensing several months of ART at a single client visit.[37,48] Immediate ART initiation compared with later ART initiation was found to be cost-effective over the long term with modest budget impact in Cote d'Ivoire,[49] and HIV-related inpatient care was cheaper in those already on ART than those untreated in South Africa and Malawi.[50,51] However, earlier treatment initiation might increase the cost of retention interventions across sub-Saharan African settings.[52] In 2016, reaching the UNAIDS 90–90–90 targets was found to be cost-effective as it cost 42% of gross domestic product per capita per life-year saved.[53] Individual analyses found cost-savings associated with specific regimen changes in children[54,55] and adults on first-line or second-line treatment.[56,57] In the only cost–benefit analysis reviewed, ART provision by a South African mining company was cost-saving from the company perspective due to reductions in health-care costs, absenteeism, and staff turnover, including benefit payments.[58] Additional cost-effective models of care included combination prevention including ART (in addition to home-based testing and linkage to care, voluntary medical male circumcision [VMMC], and condoms distribution),[59] comprehensive community-based social support for adolescents[60] and adults[61] on ART, mobile ART delivery,[62] active surveillance pharmacovigilance instead of spontaneous reporting of side-effects,[63] and private sector provision.[64] Directly administered ART (ie, treatment administered directly by a health-care worker) was found to not be cost-effective in sub-Saharan Africa.[65] Integration of maternal and paediatric HIV care into general maternal and child health was found to be cost-effective for South Africa,[66] and in Kenya, maternal and child health clinic costs were found to remain constant, but had fallen substantially for the ART clinic group.[67] Finally, a modelled analysis of potential future long-acting injectable ART formulations found that they could be cost-effective in adolescents and young adults in Kenya if they cost less than twice as much as oral ART.[68]

HIV testing

12 systematic and non-systematic reviews, summarising 686 papers, indicated that despite variability in cost per person tested and cost per person diagnosed across different HIV testing modalities,[69–71] HIV testing strategies are more cost-effective when analyses include linkage to treatment, especially in sub-Saharan Africa and other LMICs[72] where unit costs vary widely.[73] Costs were driven by testing approach,[74] scale of implementation,[73] integration with other health services,[75] and target population.[72,76,77] HIV testing approaches, such as social network-based approaches,[69] index testing services,[74,78] and venue-based testing,[69] were more costly due to additional efforts in reaching specific populations, higher personnel, and logistical costs. Increasing scale—either through integration with other health services, or via stand-alone large-scale community-based testing—was associated with lower cost per test, ranging from $4·97 to $72·35[75] in Africa (with higher values observed during the early phase of HIV testing in South Africa) and from $2·61 to $9·76[75] in Asia. Across settings, provider-initiated testing and counselling was found to cost less than half as much as client-initiated testing and counselling.[73,75] Point-of-care testing has proven to be a cost-effective option for HIV-exposed infants.[79] HIV self-testing (see the third paper[80] in this Series)—whether conducted at facilities, through secondary or index distribution, or home-based testing—exhibits lower costs per person tested (ranging from $1·09 to $155) than standard HIV testing;[74,81] however, sensitisation and promotion can raise costs in some settings.[74] Additionally, HIV self-testing has higher per-client costs once linkage to care is included, as a positive self-test result requires follow-up services.[81] HIV self-testing costs also vary widely by population. Caregiver-assisted HIV self-testing for infants was more costly than standard testing,[71] whereas targeted HIV self-testing for young adults was generally cost-effective in high-prevalence countries, with variations owing to kit costs, health-care infrastructure, training, and distribution.[72] For MSM and female sex workers, HIV self-testing incurred higher costs owing to targeting but can remain cost-effective when kit prices are competitive and detection rates are optimised by prioritising high-yield settings such as STI clinics or testing partners of index cases.[77]

Studies not included in the reviews confirmed that HIV self-testing reduces the client's economic burden, although costs vary widely across countries and distribution channels, and are higher than facility-based testing when considering cost per positive individual identified.[82–84] The secondary distribution of HIV self-testing kits to partners of ART patients had the largest impact in terms of life-years saved, but was one of the least cost-effective strategies.[85] Civil society organisation-led HIV self-testing kit provision to key populations including MSM, female sex workers, and people who inject drugs showed relatively high costs due to contextual challenges, including safety concerns; scaling up services was estimated to reduce average costs by 26–60%.[86] HIV self-testing distribution costs were reduced through community-led approaches,[87,88] peer networks including key population distribution,[89–92] optimised distribution channels,[76,85,91] reduced personnel

and facility costs,[93] integration within existing facilities[94–96] and with other testing modalities such as home-based testing,[93] secondary distribution to absent people during home visits[97] and to partners of pregnant women,[93,98,99] and focusing on areas with undiagnosed HIV prevalence above 3%.[100] Facility-based HIV testing costs also varied across settings. Mobile clinics were more expensive per test due to higher operational and logistical expenses.[101] Home-based testing with lower infrastructure requirements and high uptake among hard-to-reach groups was cost-effective for reaching rural and underserved populations in high-prevalence settings, although costs can grow with large-scale coverage.[59,102–107] Facility-based and provider-initiated testing benefits from economies of scale, especially in densely populated or high-prevalence areas, making it a cost-effective approach to meet universal testing goals.[108–112] One multicountry study showed that average costs per client tested or diagnosed for testing in antenatal clinics varied with positivity rates and staff costs.[113] The cost of HIV testing in incarcerated populations in South Africa and Zambia[114] was higher than facility-based HIV testing because of the additional security required and there being no integration with other services. Early infant diagnosis at birth and at age 6 weeks[115,116] and maternal ART initiation[117] were found to be cost-effective if using specific point-of-care early infant diagnosis platforms, substantially lowering testing costs compared with central laboratory-based early infant diagnosis.[118]

HIV prevention

Six systematic or scoping reviews explored the cost and value for money of biomedical, non-surgical prevention interventions, which spanned 463 papers, some of which were themselves systematic reviews.[119–122] Additionally, we identified 32 individual papers that were not discussed in the reviews. Most papers focused on oral PrEP, with a minority covering injectable PrEP and other products. The evidence base is largely from southern and eastern Africa.

Targeted delivery of oral PrEP to key populations including MSM, female sex workers, and young men and women at high risk is likely to be cost-effective across settings,[119,123–125] as is delivery in concentrated epidemics.[126,127] However, the additional costs of accessing these vulnerable populations at risk of HIV can be considerable.[128,129] Evidence suggests that age-targeted delivery of oral PrEP and the dapivirine ring is also likely to be cost-effective.[72,130–132] Although long-acting injectables, such as cabotegravir and lenacapavir, have the potential to be very effective, their value for money will largely depend on their ultimate price.[133–136] Vaccines and broadly neutralising antibody-based prevention, once available, are potentially cost-effective, although considerable uncertainty surrounds these estimates due to a scarcity of data on both cost and effectiveness.[119,137,138] The delivery of oral PrEP through community-based and integrated delivery strategies (eg, incorporating PrEP and ART delivery strategies and joint HIV and tuberculosis interventions) was considered cost-effective in multiple settings.[139–143] Increasing client volume could facilitate economies of scale, driving down unit costs.[123,144,145] Task shifting (eg, in nurse-led PrEP provision) could also reduce costs and accelerate PrEP delivery expansion.[144]

Three systematic and non-systematic reviews of VMMC, covering a total of 206 papers, as well as 31 individual papers not yet included in other reviews, confirmed that scaling up VMMC could dramatically reduce HIV infections, especially among males aged 15–29 years.[146,147] High costs in mobile models were driven by personnel and consumables.[148–152] Delivering VMMC at scale and task shifting reduced costs in sub-Saharan African countries with high HIV prevalence, whereas hospital-based delivery, greater recruitment of older men (aged ≥30 years), and inclusion of outreach services increased costs.[148,149,153–155] VMMC was cost-effective in 68% of sub-Saharan African model settings, and cost-saving in countries such as South Africa and Malawi over a 50-year period; however, its impact could vary based on a variety of factors including HIV incidence, VMMC programme implementation, individual risk factors, and the presence of other co-interventions.[156]

STIs

The ten systematic and non-systematic reviews included, along with an earlier systematic review from 2006,[157] and an unpublished review,[158] collectively summarised 104 papers. Most reviews focused on STI screening and treatment, with few addressing prevention interventions and antimicrobial resistance. Two reviews on STI prevention noted that many HIV prevention interventions also target STIs; however, due to the greater and more widely recognised health and economic burden of HIV, the STI-related benefits of these interventions are often under-reported or overlooked in evaluations.[159,160] Integrating STI and HIV prevention interventions, especially among groups such as female sex workers,[159] could enhance the cost-effectiveness of STI control programmes by leveraging HIV prevention benefits.[160] Antimicrobial resistance considerations could substantially alter cost-effectiveness estimates and influence treatment recommendations for gonorrhoea and other STIs.[161] However, robust antimicrobial resistance costing data and a standardised methodology for economic evaluations that incorporate antimicrobial resistance effects are scarce.

STI prevention, screening, and management

A modelling study of 81 countries found that increasing male condom use was a cost-effective intervention for preventing HIV, STIs, and unintended pregnancies.[162]

Syphilis screening in pregnancy was consistently cost-effective compared with no screening,[160,163–165] and rapid

point-of-care testing in the clinic was found to be more cost-effective than off-site laboratory testing, particularly in high-incidence settings with minimal laboratory access.[163,164] Additionally, a meta-regression across 128 countries ranked antenatal syphilis screening as having the lowest median ICER among interventions for HIV, malaria, and tuberculosis in 81 (63%) of these countries, with ICERs ranging from $3 (IQR $2–4) per DALY averted in Equatorial Guinea to $3473 (2244–5222) in Ukraine.[17]

The cost-effectiveness of causation versus syndromic management for other curable STIs was less substantiated in the literature. Several reviews on STI point-of-care testing highlighted prohibitive costs of the currently available instruments and assays, limiting LMIC uptake.[166–168] Experts convened during a STAR STI Clinical Trial Group programmatic meeting arrived at a consensus target price of $1 per test for low-resource settings, well below current technology costs.[167] There was little evidence of the cost-effectiveness of point-of-care causation testing versus off-site testing beyond one paper suggesting off-site testing is currently more cost-effective for curable STIs.[166]

A 2006 review estimated the median cost per treated curable STI case at $17·80 (cost from 2004).[157] An update of that review reported a lower median cost of $4·15 per diagnosed and treated curable STI case (cost from 2015).[158] Both reviews highlighted incomplete data from many studies, which might explain the variation in cost estimates. Additionally, the reviews found that the service delivery mode impacted costs, with clinics incurring lower costs than outreach services; however, cost-effectiveness would highly depend on the STI prevalence in groups targeted.

Individual studies not included in the reviews supported several findings from the reviews and provided additional insights. The cost-effectiveness of antenatal syphilis screening compared with no screening was confirmed, especially in contexts of high prevalence,[169] high incidence,[170] and strong adherence, implying low loss to follow-up and high treatment completion,[171] resulting in lower costs and ICERs. Interventions targeting key populations, such as behavioural programmes promoting safe sex among female sex workers[172] and screening for people who are incarcerated,[173] were found to be more cost-effective than current syndromic management practices. In contrast, among MSM and female sex workers in Papua New Guinea, syndromic management, condom distribution, and contact tracing were found to be more cost-effective than screening; however, costs for all interventions were below $0·50 per infection averted.[174] Additionally, among MSM in Zimbabwe, self-testing for syphilis showed lower costs per person tested compared with facility-based testing; however, no evidence was provided on acceptable price points for broader adoption.[175]

Several strategies have been identified to reduce costs per case for *Neisseria gonorrhoea* and *Chlamydia trachomatis* causation testing, including using in-house PCR testing rather than commercial tests,[176] using a pooling of samples for women,[177] performing GeneXpert testing in a centralised laboratory instead of point-of-care,[178] and targeting screening based on risk factors.[179] In Botswana, a mixed approach (ie, a hub-and-spoke approach that offers point-of-care testing at high-volume sites that act as centralised laboratory hubs for lower-volume sites [known as spokes] in their region) using GeneXpert testing among pregnant women resulted in lower costs per case averted compared with centralised or point-of-care testing and syndromic management.[180] A new rapid point-of-care genital inflammation test in women, combined with syndromic management, was the most cost-effective strategy for screening in South Africa, outperforming combinations of genital inflammation test with on-site GeneXpert or off-site PCR testing, regardless of variations in lost to follow-up rates.[181]

HPV and hepatitis B virus screening and vaccination

The cost-effectiveness of HPV vaccination and screening in LMICs were found to depend on delivery costs, number of doses, type of delivery strategy, coverage levels, and types of outcomes included—specifically whether analyses considered HPV-related cancers and genital warts. Although delivery costs varied widely, with procurement and human resources as key contributors,[182] vaccination remained highly cost-effective for young girls (typically aged 9–13 years).[183,184] In contrast, evidence on the cost-effectiveness of HPV vaccination for boys in LMICs is insufficient and inconclusive, with fewer than three studies identified across all reviews that have examined this question.[184,185] Combining vaccination with cost-effective screening methods, such as visual inspection of the cervix with acetic acid or HPV testing, offered greater impact, particularly with self-collection of samples by the patient, as an alternative to clinician-collected samples, achieving more than 50% coverage.[184,186,187] Competitive vaccine pricing and donor support are crucial for maximising cost-effectiveness in high-burden LMICs.[185]

Universal infant hepatitis B virus vaccination was cost-effective or cost-saving compared with no vaccination.[188] For adults in LMICs, screening combined with treatment, or with catch-up vaccination for younger adults, was found to be cost-effective compared with having no screening programme.[189] Antiviral therapies were highly cost-effective, and expanding treatment eligibility reduced late-stage liver disease and simplified diagnosis.[190] A reasonably priced hepatitis B virus cure could also be cost-effective, especially in LMICs.[191]

Contraception and safe abortion

Cost-effectiveness for contraception is typically measured through unintended pregnancies averted, the resulting short-term cost-savings to the health system, and longer term social and economic impacts.[8] Well-established return on investment analyses in family planning

Panel 2: Examples of integration making interventions cost-saving or more cost-effective

Health economics differentiate whether an intervention is cost-saving (ie, it reduces overall costs for the payer, be it the provider, the patient, or society) or cost-effective (ie, more costly but also more effective than what it is compared with; predefined thresholds set by local or international decision makers are then used to determine whether the additional benefit is worth the additional cost).

Integration of the following interventions was found to be cost-saving:

- Maternal and paediatric HIV care into general maternal and child health care in Kenya[67]
- HIV testing with other health services in African and Asian countries[73,75]
- HIV self-test distribution in existing primary health-care facilities in Malawi, South Africa, Zambia, and Zimbabwe[94–96]
- HIV self-test distribution with home-based testing in South Africa[93]
- Dual rapid diagnostic testing for HIV and syphilis at antenatal clinic visits in Kenya, South Africa, and Colombia[165]

Integration of the following interventions was found to be cost-effective under different thresholds:

- Maternal and paediatric HIV care into general maternal and child health care in South Africa[6]
- Sexually transmitted infection (STI) and HIV prevention,[160] especially in female sex workers,[159] in different countries
- Contraception and HIV services[193]
- Contraception and STI management in a mobile clinic in South Africa[194]
- HIV testing into HIV treatment in Zambia and South Africa[59,96] (community-based rapid HIV testing and referral to treatment at a government facility with additional support and provider-initiated testing by trained community health workers)
- HIV prevention[138]
- STI prevention[195] (integration of human papillomavirus and *Chlamydia trachomatis* prevention through condom distribution and human papillomavirus vaccination)
- Contraception and STI management into human papillomavirus services[194] (HIV counselling and testing, syndromic management of STIs with onward referral, breast examinations, provision of condoms, contraceptives, and general health education into mobile human papillomavirus screening vans)
- STI with other services in sub-Saharan Africa[187,196,197] (human papillomavirus self-sampling, cervical cancer screening, and HIV testing with family planning or antenatal clinic services)



Figure 2: **Accelerated approval pathway for long-acting cabotegravir in Zimbabwe**
Reproduced from Murombedzi and colleagues.[200]

suggest that for every $1 invested in contraceptive care in LMICs, the health system saves $2·48–3·21,[12] whereas the longer term annual benefits through reduced maternal and infant mortality and economic growth have been independently estimated to be $120 per dollar spent[192] (appendix p 3). One systematic review found that it is cost-effective to scale up family planning interventions, and that cost-effectiveness was driven by increasing coverage in high HIV prevalence settings, and by improving integration with HIV services.[193]

In addition, safe abortion care is a key cost-effective investment; the scoping review on SRHR found seven country-based studies that consistently showed safe abortion was cost-effective, particularly for the use of manual vacuum aspiration and misoprostol for abortion in the first trimester.[16]

Summary of findings

Cost drivers

Our literature review identified key factors increasing intervention costs from the provider perspective (ie, cost drivers), based on the reported results of sensitivity analyses. Across interventions and contexts, the most often identified cost driver was staff time, followed by drug and laboratory monitoring costs for ART, diagnostic and supply costs (in particular the cost of HIV and STI self-test kits), and supplies and outreach activities for HIV prevention.

Factors improving cost-effectiveness

Our review identified factors that increase the cost-effectiveness of services (panel 2), including expanding the number of eligible population groups; expanding



Figure 3: **Cost accruing to different payers along the care spectrum**
The size of the coloured boxes represents the tentative size of costs accruing to each payer.

Panel 3: The economic case for integration

Integration of sexual and reproductive health and rights services and systems into countries' existing primary health-care platforms is often suggested as a solution to funding declines across all areas of sexual and reproductive health and rights and the ensuing need for increased country ownership and domestic funding. In economic theory, providing intervention A together with intervention B should reduce the cost of this integrated intervention AB below the combined cost of interventions A and B, owing to economies of scope (ie, fixed resources, such as staff and space, can be shared and thus reduced; figure 4A). Integration also reduces costs for patients who only have to travel once to obtain two or more services. However, knowledge gaps on the economics of integration remain. A review of the economic evidence on HIV integration found that, although integration generally led to lower unit costs and tended to be cost-effective, the pathways of integration are not well understood and are likely to be highly context-specific.[207] Case studies suggest that although integration tended to decrease indirect unit costs, there was considerable uncertainty around the effect on above-service delivery and above-facility level costs and other shared resources,[207] potentially annulling the cost-saving effects of integration (figure 4B, C). Importantly, integration of new interventions needs to be carefully monitored in order to not overwhelm existing services and health-care providers and, as a result, reduce the quality of both services. See the appendix (pp 8–9) for other aspects of integration with primary health care and universal health coverage.

coverage, uptake, and demand, including through community provision; improving retention in care[139,172,198,199] and earlier care initiation;[49,115–117] and integrated programming (panel 2). Offering services in high-prevalence settings also generally results in improved cost-effectiveness.

Key recommendations for future SRHR policy, funding, and markets

Policy and regulation imperatives

The provision of cost-effective interventions requires a stable and committed policy environment allowing for flexible, rapid regulatory approvals of novel products and interventions. Both the COVID-19 pandemic (in regard to fast-tracking approvals of products, such as vaccines and novel drugs) and the accelerated approval for injectable long-acting cabotegravir for PrEP can serve as lessons learned. In 2022, Zimbabwe became the first African country to approve long-acting cabotegravir, as its Medicines Control Authority was able to register it within 159 days instead of its median time of 1673 days (figure 2).[200] The following factors and those in the appendix (p 7) are imperative for rapid regulatory approval: first, shorten timelines to regulatory approval, guideline development, and implementation to allow rapid enough scale-up for prevention products to yield the cost-effectiveness estimated in the studies presented here. Second, close all policy gaps. Expanding contraceptive and abortion care in particular requires addressing gaps in financing and policy that restrict access to crucial services, such as safe abortion care and access for marginalised populations, including adolescents. Third, coordinate approval regionally. Policy makers in high HIV prevalence settings should enable in-country or coordinated regional regulatory approval to be sought as soon as trial results are finalised, and health technology assessment, budgeting, tendering, and supply-chain management processes should be prepared alongside and initiated immediately after approval.[201,202]

Programming imperatives

The cost-effectiveness of interventions centrally depends on sufficient uptake and demand, calling for health systems and programmes that are nimbler and more responsive to users' needs than what is currently the case. Several aspects will need to be implemented (appendix p 7). First, deliver services outside of facilities. Our literature review suggests that most HIV, STI, contraceptive, and abortion interventions can be safely and effectively delivered by lower-level cadres in health facilities or in the community, through community health-care workers, mobile outreach, or in community pharmacies, potentially improving health outcomes and cost-effectiveness.[142] Second, foster user engagement in self-care. Self-care allows further decentralisation and democratisation of health, for example through provision of self-testing and health education via mobile phones.[203] New SRHR self-care technologies include HIV self-testing, STI self-swabbing, self-injectable contraceptives

(see the second paper[204] in this Series), and self-managed abortion.[205] Although this self-care can reduce transportation costs and other barriers, some new costs, such as those of supplies or internet connectivity, will now accrue to the patient as will the costs of linkage to care and potential onward treatment for those with positive results. (figure 3). Third, build prevention systems, not single interventions. The future product landscape will increasingly change to one of several available options, allowing for a degree of user choice. Health systems, and economic analyses, need to consider complex dynamic prevention systems, taking into account baskets of interventions and switching between technologies according to individuals' evolving needs, preferences, and risk, if funding allows.[206] Fourth, create demand for a plethora of options. Prevention systems allow patients to choose from a wide selection of HIV prevention options. These systems would require tailored messaging and demand creation for the pipeline overall instead of for individual products, allowing users to immediately switch to new options as they enter individual countries' markets. Fifth, integrate programmes. Although integrating SRHR interventions into other programmes might reduce provider costs (panel 3), other important benefits, including those to individual health and health systems outcomes, have been systematically documented.[208] Demand and ease of access will be served by integrating SRHR interventions with each other, but also with services such as maternal and child health.



Figure 4: **Potential economies of scope in integration**
Current evidence (panel 2) suggests that although integration might reduce costs below the sum of the cost of the individual services, due to the sharing of fixed resources (A), the cost of the combined service might also stay the same (B) or increase (C), especially once above-facility costs are included.



Figure 5: **Accelerating product introduction for HIV prevention**
Reproduced from AVAC.[202] Question marks denote the timing of anticipated but still uncertain milestones. LMICs=low-income and middle-income countries.

Market imperatives: how to shape markets for SRHR services

If cost-effective interventions are to be delivered at scale, a number of market factors will need to be aligned with this goal. Market factors, such as generic and local manufacturing and voluntary licences, can be brought to bear towards that goal across the following intervention areas: first, STI services. Currently, demand for services, diagnostics, and treatments for STIs outstrips production by far. Shortages of antimicrobials for STI treatment are increasing worldwide due to manufacturing challenges, quality control issues, and market pressures, all of which negatively impact patient outcomes and escalate health-care costs.[209] Given the global STI burden, large-scale manufacturing offers the potential for economies of scale to reduce unit costs, and targeting interventions alleviates short-term production constraints. Other potential solutions include onshoring production, building strategic stockpiles, and offering incentives to manufacturers to secure a stable supply of essential antimicrobials, and voluntary licensing agreements, in particular between patent holders of STI diagnostics and local manufacturers.[168,210] Second, contraceptive care. The UN Population Fund Supplies Match Fund for contraceptive supplies launched by the UN Population Fund Supplies Partnership allows the UN Population Fund to match domestic contributions to quality-assured commodity procurement. A total of 44 countries have signed on, and 15 have thus far contributed at a level where they could access the match fund, unlocking an additional $10·5 million across the 15 countries.[211] Third, HIV care. Both WHO guidelines and national regulatory approvals happened far more quickly with long-acting cabotegravir than with oral PrEP (figure 5). However, minimal supplies from the originator company, delays in voluntary licences for generic manufacturers, and the focus on small-scale implementation studies (to the detriment of large-scale roll-out) have reduced the likelihood of an injectable PrEP option making an impact on public health.[212] Injectable lenacapavir, which is as effective as long-acting cabotegravir, but requires an injection only every 6 months as opposed to every 2 months,[213,214] demands even greater speed, scale, and equity in planning for its introduction. This initiation can only happen with strategic actions coordinated among all stakeholders.[202]

Conclusions

In the context of constrained funding for HIV and STI care, contraception implementation, and abortion care, it is

imperative to implement and scale up cost-effective approaches to service delivery, including integrated delivery, task-sharing, and self-care interventions. Under reduced funding, prioritising health in domestic budgets and political leadership is essential, alongside inter-sectoral and intra-sectoral collaboration. Past evidence has shown that SRHR services are among the most cost-effective services in global health, and that efficiency has increased over the past decades; however, additional funding from outside donors will continue to be needed.[215] As resource constraints increase, the global community will need to ensure that it does not lose hard-won ground towards improving health, safeguarding human rights, and controlling the spread of infectious diseases. Defunding services now merely moves funding needs into the future, and increases the amount required eventually—all while the number of deaths and suffering are likely to increase sharply.

Contributors

GM-R and LJ wrote the first draft of the manuscript. LJ, KSn, EM, and EAS conducted the literature review and summarised its results. JJO, JC, MW, VW, and KSt added sections on aspects of the funding landscape and key recommendations. JH substantially edited the manuscript and assisted with figure development. All authors reviewed several versions of the manuscript and suggested additional literature where relevant.

Declaration of interests

GM-R and LJ declare funding from the National Institutes of Health, Foundation for Innovative New Diagnostics, the Gates Foundation, and the United States Agency for International Development. JH declares funding from The Fenway Institute. KSt is a full-time staff member of WHO. KSn declares funding from Foundation for Innovative New Diagnostics and the United States Agency for International Development. KK declares funding from the United States Agency for International Development, UNAIDS, and the Global Fund to Fight AIDS, Tuberculosis and Malaria. MW is a member of the Gilead Sciences data monitoring committee for PrEP and the National Institute of Allergy and Infectious Diseases data safety monitoring board for HIV vaccines and has leadership roles in AIDS Vaccine Advocacy Coalition, TB Stakeholder Association, TB Alliance, and International AIDS Society. AP declares funding from Gates Foundation, WHO, Wellcome Trust, the National Institutes of Health, the EU, and the National Institute for Health and Care Research. RB is the Francis and Dorethea Reed Endowed Chair, declares funding from the National Institutes of Health, Gates Foundation, and from Regeneron Pharmaceutical, which covered the cost of conference abstract and manuscript writing outside the submitted work, and serves on the Gilead Sciences data monitoring committee. EAS declares funding from Gates Foundation, Norad, the Children's Investment Fund Foundation, the Government of the Netherlands, The Foreign, Commonwealth & Development Office, and the UN Population Fund. All other authors declare no competing interests. None of the funding sources had a role in the writing of the manuscript or the decision to submit it for publication. During the preparation of this work the authors used Google Gemini in order to compile the information included in the appendix. Results were reviewed against the original papers and edited by the authors. The authors take full responsibility for the content of the publication.

Acknowledgments

We thank four additional coauthors who contributed to the paper but were unable to maintain authorship due to concerns regarding the reinstated Mexico City policy. We acknowledge support through a grant from the Gates Foundation (INV-064094) for work on this publication and the entire Series.

References

1 Starrs AM, Ezeh AC, Barker G, et al. Accelerate progress—sexual and reproductive health and rights for all: report of the Guttmacher-*Lancet* Commission. *Lancet* 2018; **391:** 2642–92.
2 Wexler A, Kates J, Lief E. Donor government funding for family planning in 2022. KFF, April 24, 2024. https://www.kff.org/report-section/donor-government-funding-for-family-planning-in-2022-report/ (accessed Nov 29, 2024).
3 UNAIDS. 2024 global AIDS report—The urgency of now: AIDS at a crossroads. UNAIDS, 2024.
4 Kates J, Moss K. The outlook for PEPFAR in 2025 and beyond. KFF, Feb 20, 2025. https://www.kff.org/policy-watch/the-outlook-for-pepfar-in-2025-and-beyond/ (accessed May 9, 2025).
5 Korenromp EL, Wi T, Resch S, Stover J, Broutet N. Costing of national STI program implementation for the global STI control strategy for the health sector, 2016-2021. *PLoS One* 2017; **12:** e0170773.
6 Sully E A, Rosenberg J, Tignor M, Geddes C, Dilaverakis Fernandes A, Polis C. Adding it up 2024: investing in sexual and reproductive health in low- and middle-income countries. Guttmacher Institute, 2025. https://www.guttmacher.org/report/adding-it-up-2024-investing-sexual-and-reproductive-health-low-and-middle-income-countries. (accessed Oct 30, 2025).
7 Grulich AE, Mercer C, Sturro B, et al. Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends. *Lancet* 2025; **406:** 2100–18.
8 Family Planning 2030. Family planning and gender equality. https://www.fp2030.org/measurement-report-2023/#finance (accessed Sept 16, 2025).
9 Stover J, Sonnevelft E, Tam Y, et al. The effects of reductions in United States foreign assistance on global health. *SSRN* 2025; published online April 8. https://doi.org/10.2139/ssrn.5199076 (preprint).
10 Ten Brink D, Martin-Hughes R, Bowring AL, et al. Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study. *Lancet HIV* 2025; **12:** e346–54.
11 Ong JJ, Estcourt C, Tucker JD, Golden MR, Hocking JS, Fairley CK. How should we deliver sexual health services in the 2020s? *Sex Health* 2022; **19:** 233.
12 Guttmacher Institute. Family planning investment impact calculator. Guttmacher Institute, 2024. https://www.guttmacher.org/fp-impact-calculator (accessed Dec 6, 2024).
13 Damavandi S, Sully EA, Friedrich-Karnik A, Tignor M. Just the numbers: the impact of US international family planning assistance. Guttmacher Institute, Feb 14, 2025. https://www.guttmacher.org/2025/02/just-numbers-impact-us-international-family-planning-assistance-2024 (accessed May 22, 2025).
14 Lamontagne E, Over M, Stover J, Yakusik A, Ventelou B. The cost of inaction of failing to meet global targets to end the AIDS epidemic: looking beyond 2030. AIDS 2024, the 25th International AIDS Conference; 22–26 July 2024 (abstr WEPEE579).
15 Smela B, Toumi M, Świerk K, et al. Rapid literature review: definition and methodology. *J Mark Access Health Policy* 2023; **11:** 2241234.
16 Kaiser AH, Ekman B, Dimarco M, Sundewall J. The cost-effectiveness of sexual and reproductive health and rights interventions in low- and middle-income countries: a scoping review. *Sex Reprod Health Matters* 2021; **29:** 1983107.
17 Silke F, Earl L, Hsu J, et al. Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis. *Lancet Glob Health* 2024; **12:** e1159–73.
18 Chiu C, Johnson LF, Jamieson L, Larson BA, Meyer-Rath G. Designing an optimal HIV programme for South Africa: does the optimal package change when diminishing returns are considered? *BMC Public Health* 2017; **17:** 143.
19 Meyer-Rath G. Bridging research and policy: the economic impact of the HIV response. HE2RO, 2024. https://www.heroza.org/publications/bridging-research-and-policy-the-economic-impact-of-the-hiv-response-2/ (accessed Sept 16, 2025).
20 Gupta I, Singh D. Cost-effectiveness of antiretroviral therapy: a systematic review. *Indian J Public Health* 2020; **64** (suppl)**:** S32–38.
21 Roberts DA, Tan N, Limaye N, Irungu E, Barnabas RV. Cost of differentiated HIV antiretroviral therapy delivery strategies in sub-Saharan Africa: a systematic review. *J Acquir Immune Defic Syndr* 2019; **82** (suppl 3)**:** S339–47.

22 Mdege ND, Chindove S. Bringing antiretroviral therapy (ART) closer to the end-user through mobile clinics and home-based ART: systematic review shows more evidence on the effectiveness and cost effectiveness is needed. *Int J Health Plann Manage* 2014; **29:** e31–47.

23 Larki M, Latifnejad Roudsari R. Home-based care, the missing link in caring of patients living with HIV/AIDS and their family members: a narrative review. *Int J Community Based Nurs Midwifery* 2020; **8:** 190–208.

24 Kredo T, Adeniyi FB, Bateganya M, Pienaar ED. Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. *Cochrane Database Syst Rev* 2014; **2014:** CD007331.

25 Mdege ND, Chindove S, Ali S. The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. *Health Policy Plan* 2013; **28:** 223–36.

26 Mbeye NM, Adetokunboh O, Negussie E, Kredo T, Wiysonge CS. Shifting tasks from pharmacy to non-pharmacy personnel for providing antiretroviral therapy to people living with HIV: a systematic review and meta-analysis. *BMJ Open* 2017; **7:** e015072.

27 Decroo T, Rasschaert F, Telfer B, Remartinez D, Laga M, Ford N. Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. *Int Health* 2013; **5:** 169–79.

28 Hagey JM, Li X, Barr-Walker J, et al. Differentiated HIV care in sub-Saharan Africa: a scoping review to inform antiretroviral therapy provision for stable HIV-infected individuals in Kenya. *AIDS Care* 2018; **30:** 1477–87.

29 Liang A, Wilson-Barthes M, Galárraga O. Cost-effectiveness of differentiated care models that incorporate economic strengthening for HIV antiretroviral therapy adherence: a systematic review. *Cost Eff Resour Alloc* 2024; **22:** 46.

30 Aprilianti S, Utami AM, Suwantika AA, Zakiyah N, Azis VI. The cost-effectiveness of dolutegravir in combination with tenofovir and lamivudine for HIV therapy: a systematic review. *Clinicoecon Outcomes Res* 2024; **16:** 25–34.

31 Øgård-Repål A, Berg RC, Fossum M. Peer support for people living with HIV: a scoping review. *Health Promot Pract* 2023; **24:** 172–90.

32 Lepere P, Babington-Ashaye A, Martínez-Pérez GZ, Ekouevi DK, Labrique AB, Calmy A. How mHealth can contribute to improving the continuum of care: a scoping review approach to the case of human immunodeficiency virus in sub-Saharan Africa. *Public Health Rev* 2022; **43:** 1604557.

33 Ahmed A, Dujaili JA, Chuah LH, et al. Cost-effectiveness of anti-retroviral adherence interventions for people living with HIV: a systematic review of decision analytical models. *Appl Health Econ Health Policy* 2023; **21:** 731–50.

34 Yates T, Lantagne D, Mintz E, Quick R. The impact of water, sanitation, and hygiene interventions on the health and well-being of people living with HIV: a systematic review. *J Acquir Immune Defic Syndr* 2015; **68** (suppl 3)**:** S318–30.

35 Long LC, Rosen SB, Brennan A, et al. Treatment outcomes and costs of providing antiretroviral therapy at a primary health clinic versus a hospital-based HIV clinic in South Africa. *PLoS One* 2016; **11:** e0168118.

36 Moiana Uetela DA, Zimmermann M, Chicumbe S, et al. Cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique: a modelling study. *J Int AIDS Soc* 2024; **27:** e26275.

37 Ruhago G, Forsythe S, Van de Ven R, Apicella L. Estimating the cost and efficiency gain of rolling out a multi-month dispensing programme for antiretroviral treatment in Tanzania. *Afr J AIDS Res* 2022; **21:** 385–90.

38 Okere NE, Corball L, Kereto D, et al. Patient-incurred costs in a differentiated service delivery club intervention compared to standard clinical care in Northwest Tanzania. *J Int AIDS Soc* 2021; **24:** e25760.

39 Forsythe S, Lee B, Tarimo K, et al. HIV treatment support services in Tanzania: a cost and efficiency analysis at facility and community levels. *Afr J AIDS Res* 2019; **18:** 306–14.

40 Guthrie T, Muheki C, Rosen S, et al. Similar costs and outcomes for differentiated service delivery models for HIV treatment in Uganda. *BMC Health Serv Res* 2022; **22:** 1315.

41 Nichols BE, Cele R, Jamieson L, et al. Community-based delivery of HIV treatment in Zambia: costs and outcomes. *AIDS* 2021; **35:** 299–306.

42 Sahu M, Bayer CJ, Roberts DA, et al. Population health impact, cost-effectiveness, and affordability of community-based HIV treatment and monitoring in South Africa: a health economics modelling study. *PLOS Glob Public Health* 2023; **3:** e0000610.

43 Vadra J, Komarudin D, Prawiranegara R, Lestari M, Wisaksana R, Siregar AYM. The cost of providing hospital-based (early) antiretroviral treatment in Indonesia: what has changed in almost a decade? *AIDS Care* 2023; **35:** 131–38.

44 Resch SC, Foote JHA, Wirth KE, et al. Health impact and cost-effectiveness of HIV testing, linkage, and early antiretroviral treatment in the Botswana combination prevention project. *J Acquir Immune Defic Syndr* 2022; **90:** 399–407.

45 Siregar AYM, Tromp N, Komarudin D, et al. Costs of HIV/AIDS treatment in Indonesia by time of treatment and stage of disease. *BMC Health Serv Res* 2015; **15:** 440.

46 Desmonde S, Avit D, Petit J, et al. Costs of care of HIV-infected children initiating lopinavir/ritonavir-based antiretroviral therapy before the age of two in Cote d'Ivoire. *PLoS One* 2016; **11:** e0166466.

47 Long LC, Maskew M, Brennan AT, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. *AIDS* 2017; **31:** 1611–19.

48 Nichols BE, Cele R, Lekodeba N, et al. Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. *J Int AIDS Soc* 2021; **24:** e25692.

49 Ouattara EN, MacLean RL, Danel C, et al. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: a model-based analysis. *PLoS One* 2019; **14:** e0219068.

50 Maheswaran H, Petrou S, Cohen D, et al. Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: a prospective hospital cohort study in Malawi. *PLoS One* 2018; **13:** e0192991.

51 Long LC, Fox MP, Sauls C, Evans D, Sanne I, Rosen SB. The high cost of HIV-positive inpatient care at an urban hospital in Johannesburg, South Africa. *PLoS One* 2016; **11:** e0148546.

52 Bershteyn A, Jamieson L, Kim H-Y, et al. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. *Lancet Glob Health* 2022; **10:** e1298–306.

53 Walensky RP, Borre ED, Bekker L-G, et al. The anticipated clinical and economic effects of 90-90-90 in South Africa. *Ann Intern Med* 2016; **165:** 325–33.

54 Desmonde S, Frank SC, Coovadia A, et al. Cost-effectiveness of preemptive switching to efavirenz-based antiretroviral therapy for children with human immunodeficiency virus. *Open Forum Infect Dis* 2019; **6:** ofz276.

55 Siriruchatanon M, Liu S, Carlucci JG, Enns EA, Duarte HA. Addressing pediatric HIV pretreatment drug resistance and virologic failure in sub-Saharan Africa: a cost-effectiveness analysis of diagnostic-based strategies in children ≥3 years old. *Diagnostics* 2021; **11:** 567.

56 Boyer S, Nishimwe ML, Sagaon-Teyssier L, et al, and the 2-Lady Group. Cost-effectiveness of three alternative boosted protease inhibitor-based second-line regimens in HIV-infected patients in west and central Africa. *PharmacoEconom Open* 2020; **4:** 45–60.

57 Isah A, Chukwu PO, Abba A, et al. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre. *Afr Health Sci* 2023; **23:** 157–69.

58 Meyer-Rath G, Pienaar J, Brink B, et al. The impact of company-level ART provision to a mining workforce in South Africa: a cost-benefit analysis. *PLoS Med* 2015; **12:** e1001869.

59 Thomas R, Probert WJM, Sauter R, et al, and the HPTN 071 (PopART) study team. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial. *Lancet Glob Health* 2021; **9:** e668–80.

60 Fatti G, Jackson D, Goga AE, et al. The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: an operational research study in South Africa. *J Int AIDS Soc* 2018; **21** (suppl 1)**:** e25041.

61 McBain RK, Petersen E, Tophof N, et al. Impact and economic evaluation of a novel HIV service delivery model in rural Malawi. *AIDS* 2017; **31:** 1999–2006.

62 Miyano S, Syakantu G, Komada K, Endo H, Sugishita T. Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia. *Cost Eff Resour Alloc* 2017; **15:** 4.

63 Mann M, Mengistu A, Gaeseb J, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: a cost-utility analysis. *Drug Saf* 2016; **39:** 859–72.

64 Long LC, Girdwood S, Govender K, Meyer-Rath G, Miot J. Cost and outcomes of routine HIV care and treatment: public and private service delivery models covering low-income earners in South Africa. *BMC Health Serv Res* 2023; **23:** 240.

65 Uthman RT, Sutton AJ, Jackson LJ, Uthman OA. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis. *PLoS One* 2018; **13:** e0191465.

66 Dugdale CM, Phillips TK, Myer L, et al, and the MCH-ART Trial Team. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. *PLoS One* 2019; **14:** e0225104.

67 Larson BA, Bii M, Halim N, Rohr JK, Sugut W, Sawe F. Incremental treatment costs for HIV-infected women initiating antiretroviral therapy during pregnancy: a 24-month micro-costing cohort study for a maternal and child health clinic in Kenya. *PLoS One* 2018; **13:** e0200199.

68 Culhane J, Sharma M, Wilson K, et al. Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya. *EClinicalMedicine* 2020; **25:** 100453.

69 Choong A, Lyu YM, Johnson CC, et al. Social network-based approaches to HIV testing: a systematic review and meta-analysis. *J Int AIDS Soc* 2024; **27:** e26353.

70 Hauck K. The costs of home-based HIV testing and counselling in sub-Saharan Africa and its association with testing yield: a literature review. *Afr J AIDS Res* 2019; **18:** 324–31.

71 McGee K, Jamil MS, Siegfried N, et al. Caregiver-assisted testing with HIV self-test kits for children 18 months and older: a GRADE systematic review. *PLOS Glob Public Health* 2024; **4:** e0003588.

72 Zimmerman A, Fawole A, Shahid M, Dow D, Ogbuoji O. Evidence gaps in economic evaluations of HIV interventions targeting young people: a systematic review. *J Adolesc Health* 2024; **75:** 709–24.

73 Pineda-Antunez C, Martinez-Silva G, Cerecero-Garcia D, et al. Meta-analysis of average costs of HIV testing and counselling and voluntary medical male circumcision across thirteen countries. *Afr J AIDS Res* 2019; **18:** 341–49.

74 Ahmed N, Ong JJ, McGee K, et al. Costs of HIV testing services in sub-Saharan Africa: a systematic literature review. *BMC Infect Dis* 2024; **22** (suppl 1)**:** 980.

75 Siapka M, Remme M, Obure CD, Maier CB, Dehne KL, Vassall A. Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries. *Bull World Health Organ* 2014; **92:** 499–511.

76 McGee K, d'Elbée M, Dekova R, et al. Costs of distributing HIV self-testing kits in Eswatini through community and workplace models. *BMC Infect Dis* 2024; **22** (suppl 1)**:** 976.

77 Rivera AS, Hernandez R, Mag-Usara R, et al. Implementation outcomes of HIV self-testing in low- and middle- income countries: A scoping review. *PLoS One* 2021; **16:** e0250434.

78 Suthar AB, Ford N, Bachanas PJ, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. *PLoS Med* 2013; **10:** e1001496.

79 le Roux SM, Odayar J, Sutcliffe CG, et al. Cost-effectiveness of point-of-care versus centralised, laboratory-based nucleic acid testing for diagnosis of HIV in infants: a systematic review of modelling studies. *Lancet HIV* 2023; **10:** e320–31.

80 Peters RPH, Grinsztejn B, Celum C, et al. Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections. *Lancet* 2025; **406:** 2133–51.

81 Empringham B, Karellis A, Kashkary A, et al. How much does HIV self-testing cost in low and middle income countries? A systematic review of evidence from economic studies. *Front Public Health* 2023; **11:** 1135425.

82 Nichols BE, Offorjebe OA, Cele R, et al. Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. *J Int AIDS Soc* 2020; **23:** e25612.

83 Phillips AN, Cambiano V, Nakagawa F, et al. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. *J Int AIDS Soc* 2019; **22:** e25325.

84 Maheswaran H, Petrou S, MacPherson P, et al. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. *BMC Med* 2016; **14:** 34.

85 Jamieson L, Johnson LF, Matsimela K, et al. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. *BMJ Glob Health* 2021; **6** (suppl 4)**:** e005598.

86 d'Elbée M, Traore MM, Badiane K, et al. Costs and scale-up costs of integrating HIV self-testing into civil society organisation-led programmes for key populations in Côte d'Ivoire, Senegal, and Mali. *Front Public Health* 2021; **9:** 653612.

87 Putri WCWS, Ulandari LPS, Valerie IC, et al. Costs and scale-up costs of community-based oral HIV self-testing for female sex workers and men who have sex with men in Jakarta and Bali, Indonesia. *BMC Health Serv Res* 2024; **24:** 114.

88 Indravudh PP, Fielding K, Sande LA, et al. Pragmatic economic evaluation of community-led delivery of HIV self-testing in Malawi. *BMJ Glob Health* 2021; **6** (suppl 4)**:** e004593.

89 Lu IJ, Silhol R, d'Elbée M, et al, and the ATLAS Team. Cost-effectiveness analysis of community-led HIV self-testing among key populations in Côte d'Ivoire, Mali, and Senegal. *J Int AIDS Soc* 2024; **27:** e26334.

90 Okoboi S, Castelnuovo B, Van Geertruyden J-P, et al. Cost-effectiveness of peer-delivered HIV self-tests for MSM in Uganda. *Front Public Health* 2021; **9:** 651325.

91 Traore MM, Badiane K, Vautier A, et al. Economic analysis of low volume interventions using real-world data: costs of HIV self-testing distribution and HIV testing services in West Africa from the ATLAS Project. *Front Health Serv* 2022; **2:** 886513.

92 Matsimela K, Sande LA, Mostert C, et al. The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa. *BMJ Glob Health* 2021; **6** (suppl 4)**:** e005019.

93 Johnson LF, van Rensburg C, Govathson C, Meyer-Rath G. Optimal HIV testing strategies for South Africa: a model-based evaluation of population-level impact and cost-effectiveness. *Sci Rep* 2019; **9:** 12621.

94 Sande LA, Matsimela K, Mwenge L, et al. Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe. *BMJ Glob Health* 2021; **6** (suppl 4)**:** e005191.

95 Cambiano V, Ford D, Mabugu T, et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. *J Infect Dis* 2015; **212:** 570–77.

96 Bristow CC, Larson E, Anderson LJ, Klausner JD. Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study. *Sex Transm Infect* 2016; **92:** 340–46.

97 Amstutz A, Matsela L, Lejone TI, Kopo M, Glass TR, Labhardt ND. Reaching absent and refusing individuals during home-based HIV testing through self-testing-at what cost? *Front Med* 2021; **8:** 653677.

98 Zishiri V, Conserve DF, Haile ZT, et al. Secondary distribution of HIV self-test kits by HIV index and antenatal care clients: implementation and costing results from the STAR Initiative in South Africa. *BMC Infect Dis* 2023; **22** (suppl 1)**:** 971.

99 Bulterys MA, Mujugira A, Nakyanzi A, et al. Costs of providing HIV self-test kits to pregnant women living with HIV for secondary distribution to male partners in Uganda. *Diagnostics* 2020; **10:** 318.

100 Cambiano V, Johnson CC, Hatzold K, et al, and the Working Group on Cost Effectiveness of HIV Self-testing in Southern Africa. The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis. *J Int AIDS Soc* 2019; **22** (suppl 1)**:** e25243.

101 de Beer I, Chani K, Feeley FG, Rinke de Wit TF, Sweeney-Bindels E, Mulongeni P. Assessing the costs of mobile voluntary counseling and testing at the work place versus facility based voluntary counseling and testing in Namibia. *Rural Remote Health* 2015; **15:** 3357.

102 Bousmah MA, Iwuji C, Okesola N, et al, and the ANRS 12249 TasP Study Group. Costs and economies of scale in repeated home-based HIV counselling and testing: evidence from the ANRS 12249 treatment as prevention trial in South Africa. *Soc Sci Med* 2022; **305:** 115068.

103 Vasantharoopan A, Maheswaran H, Simms V, et al. A costing analysis of B-GAP: index-linked HIV testing for children and adolescents in Zimbabwe. *BMC Health Serv Res* 2021; **21:** 1082.

104 Lasry A, Bachanas P, Suraratdecha C, et al. Cost of community-based HIV testing activities to reach saturation in Botswana. *AIDS Behav* 2019; **23:** 875–82.

105 Labhardt ND, Ringera I, Lejone TI, et al. Effect and cost of two successive home visits to increase HIV testing coverage: a prospective study in Lesotho, Southern Africa. *BMC Public Health* 2019; **19:** 1441.

106 Chang W, Chamie G, Mwai D, et al. Implementation and operational research: cost and efficiency of a hybrid mobile multidisease testing approach with high HIV testing coverage in East Africa. *J Acquir Immune Defic Syndr* 2016; **73:** e39–45.

107 Tabana H, Nkonki L, Hongoro C, et al. A cost-effectiveness analysis of a home-based HIV counselling and testing intervention versus the standard (facility based) HIV testing strategy in rural South Africa. *PLoS One* 2015; **10:** e0135048.

108 Songane M, Magaia CC, Couto A, et al. HIV community index testing reaches proportionally more males than facility-based testing and is cost-effective: a study from Gaza province, Mozambique. *PLoS One* 2023; **18:** e0286458.

109 Stanic T, McCann N, Penazzato M, et al. Cost-effectiveness of routine provider-initiated testing and counseling for children with undiagnosed HIV in South Africa. *Open Forum Infect Dis* 2021; **9:** ofab603.

110 Suraratdecha C, MacKellar D, Steiner C, et al. Cost-outcome analysis of HIV testing and counseling, linkage, and defaulter tracing services in Bukoba, Tanzania. *AIDS Care* 2024; **36:** 744–51.

111 Cham HJ, MacKellar D, Maruyama H, et al. Methods, outcomes, and costs of a 2.5 year comprehensive facility-and community-based HIV testing intervention in Bukoba Municipal Council, Tanzania, 2014-2017. *PLoS One* 2019; **14:** e0215654.

112 Mwenge L, Sande L, Mangenah C, et al. Costs of facility-based HIV testing in Malawi, Zambia and Zimbabwe. *PLoS One* 2017; **12:** e0185740.

113 Bautista-Arredondo S, Sosa-Rubí SG, Opuni M, et al, and the ORPHEA study team. Costs along the service cascades for HIV testing and counselling and prevention of mother-to-child transmission. *AIDS* 2016; **30:** 2495–504.

114 Mukora R, Smith HJ, Herce ME, et al. Costs of implementing universal test and treat in three correctional facilities in South Africa and Zambia. *PLoS One* 2022; **17:** e0272595.

115 Frank SC, Cohn J, Dunning L, et al. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. *Lancet HIV* 2019; **6:** e182–90.

116 Francke JA, Penazzato M, Hou T, et al. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. *J Infect Dis* 2016; **214:** 1319–28.

117 Dunning L, Gandhi AR, Penazzato M, et al. Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis. *J Int AIDS Soc* 2021; **24:** e25651.

118 Mukherjee S, Cohn J, Ciaranello AL, et al. Estimating the cost of point-of-care early infant diagnosis in a program setting: a case study using Abbott m-PIMA and cepheid GeneXpert IV in Zimbabwe. *J Acquir Immune Defic Syndr* 2020; **84** (suppl 1)**:** S63–69.

119 Bozzani FM, Terris-Prestholt F, Quaife M, et al. Costs and cost-effectiveness of biomedical, non-surgical HIV prevention interventions: a systematic literature review. *PharmacoEconomics* 2023; **41:** 467–80.

120 Kennedy CE, Yeh PT, Atkins K, Ferguson L, Baggaley R, Narasimhan M. PrEP distribution in pharmacies: a systematic review. *BMJ Open* 2022; **12:** e054121.

121 Murphy L, Bowra A, Adams E, et al. PrEP policy implementation gaps and opportunities in Latin America and the Caribbean: a scoping review. *Ther Adv Infect Dis* 2023; **10:** 20499361231164030.

122 National Institute for Health and Care Excellence. Reducing sexually transmitted infections (STIs). National Institute for Health and Care Excellence, 2022.

123 Manguro GO, Kioko UM, Githinji G, et al. Costs and cost drivers of comprehensive sexual reproductive health services to female sex workers in Kenya. *BMC Health Serv Res* 2024; **24:** 822.

124 Stone J, Bothma R, Gomez GB, et al. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis. *J Int AIDS Soc* 2023; **26:** e26063.

125 Bansi-Matharu L, Revill P, Taramusi I, et al. The effect on HIV transmission and cost-effectiveness of programmes for female sex workers in East, Central, and Southern Africa: a modelling study. *Lancet Glob Health* 2024; **12:** e1436–45.

126 Phillips AN, Cambiano V, Johnson L, et al. Potential impact and cost-effectiveness of condomless-sex-concentrated PrEP in KwaZulu-Natal accounting for drug resistance. *J Infect Dis* 2021; **223:** 1345–55.

127 Ten Brink DC, Martin-Hughes R, Minnery ME, et al. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: a modelling study. *PLoS One* 2022; **17:** e0268240.

128 Hendrickson C, Long LC, van Rensburg C, et al. The early-stage comprehensive costs of routine PrEP implementation and scale-up in Zambia. *PLOS Glob Public Health* 2022; **2:** e0001246.

129 Opuni M, Sanchez-Morales JE, Figueroa JL, et al. Estimating the cost of HIV services for key populations provided by the LINKAGES program in Kenya and Malawi. *BMC Health Serv Res* 2023; **23:** 337.

130 Glaubius RL, Hood G, Penrose KJ, et al. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. *Clin Infect Dis* 2016; **63:** 539–47.

131 Alsallaq RA, Buttolph J, Cleland CM, et al. The potential impact and cost of focusing HIV prevention on young women and men: a modeling analysis in western Kenya. *PLoS One* 2017; **12:** e0175447.

132 Glaubius R, Ding Y, Penrose KJ, et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. *J Int AIDS Soc* 2019; **22:** e25282.

133 Wu L, Kaftan D, Wittenauer R, et al. Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis. *Lancet HIV* 2024; **11:** e765–73.

134 Jamieson L, Johnson LF, Nichols BE, et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. *Lancet HIV* 2022; **9:** e857–67.

135 Hill A, Levi J, Fairhead C, et al. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. *J Antimicrob Chemother* 2024; **79:** 2906–15.

136 Zhao R, Fairley CK, Cook AR, et al. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis. *Lancet Glob Health* 2024; **12:** e243–56.

137 Dugdale CM, Ufio O, Alba C, et al. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. *J Int AIDS Soc* 2023; **26:** e26052.

138 Moodley N, Gray G, Bertram M. The price of prevention: cost effectiveness of biomedical HIV prevention strategies in South Africa. *Clin Res HIV AIDS* 2016; **3:** 1031.

139 Suraratdecha C, Stuart RM, Manopaiboon C, et al. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. *J Int AIDS Soc* 2018; **21** (suppl 5)**:** e25129.

140 Soe KM, Hauck K, Jiamton S, Kongsin S. The cost of community outreach HIV interventions: a case study in Thailand. *BMC Public Health* 2022; **22:** 20.

141 Peebles K, Mugwanya KK, Irungu E, et al, and the Partners Scale-Up Project Team. Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public sector. *BMC Health Serv Res* 2021; **21:** 823.

142 Phillips AN, Bershteyn A, Revill P, et al, and the HIV Modelling Consortium. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. *Lancet HIV* 2022; **9:** e353–62.

143 Versteegh L, Amatavete S, Chinbunchorn T, et al. The epidemiological impact and cost-effectiveness of key population-led PrEP delivery to prevent HIV among men who have sex with men in Thailand: a modelling study. *Lancet Reg Health Southeast Asia* 2022; **7:** 100097.

144 Kohler S, Dalal S, Hettema A, Matse S, Bärnighausen T, Paul N. Human resource needs and costs for HIV pre-exposure prophylaxis provision in nurse-led primary care in Eswatini and opportunities for task sharing. *Hum Resour Health* 2022; **20:** 75.

145 Wanga V, Peebles K, Obiero A, et al. Cost of pre-exposure prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya. *PLoS One* 2021; **16:** e0249625.

146 Stegman P, Stirling B, Corner B, et al. Voluntary medical male circumcision to prevent HIV: modelling age prioritization in Namibia. *AIDS Behav* 2019; **23** (suppl 2)**:** 195–205.

147 Haacker M, Fraser-Hurt N, Gorgens M. Effectiveness of and financial returns to voluntary medical male circumcision for HIV prevention in South Africa: an incremental cost-effectiveness analysis. *PLoS Med* 2016; **13:** e1002012.

148 Davis SM, Owuor N, Odoyo-June E, et al. Making voluntary medical male circumcision services sustainable: findings from Kenya's pilot models, baseline and year 1. *PLoS One* 2021; **16:** e0252725.

149 Kripke K, Okello V, Maziya V, et al. Voluntary medical male circumcision for HIV prevention in Swaziland: modeling the impact of age targeting. *PLoS One* 2016; **11:** e0156776.

150 Tchuenche M, Palmer E, Haté V, et al. The cost of voluntary medical male circumcision in South Africa. *PLoS One* 2016; **11:** e0160207.

151 Schutte C, Tshimanga M, Mugurungi O, et al. Comparative cost analysis of surgical and PrePex device male circumcision in Zimbabwe and Mozambique. *J Acquir Immune Defic Syndr* 2016; **72** (suppl 1)**:** S96–100.

152 Larson B, Tindikahwa A, Mwidu G, Kibuuka H, Magala F. How much does it cost to improve access to voluntary medical male circumcision among high-risk, low-income communities in Uganda? *PLoS One* 2015; **10:** e0119484.

153 Bautista-Arredondo S, Pineda-Antunez C, Cerecero-Garcia D, et al. Moving away from the "unit cost". Predicting country-specific average cost curves of VMMC services accounting for variations in service delivery platforms in sub-Saharan Africa. *PLoS One* 2021; **16:** e0249076.

154 Galárraga O, Wamai RG, Sosa-Rubí SG, et al. HIV prevention costs and their predictors: evidence from the ORPHEA Project in Kenya. *Health Policy Plan* 2017; **32:** 1407–16.

155 Korenromp EL, Bershteyn A, Mudimu E, et al. The impact of the program for medical male circumcision on HIV in South Africa: analysis using three epidemiological models. *Gates Open Res* 2021; **5:** 15.

156 Bansi-Matharu L, Mudimu E, Martin-Hughes R, et al. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. *Lancet Glob Health* 2023; **11:** e244–55.

157 Terris-Prestholt F, Vyas S, Kumaranayake L, Mayaud P, Watts C. The costs of treating curable sexually transmitted infections in low- and middle-income countries: a systematic review. *Sex Transm Dis* 2006; **33** (suppl)**:** S153–66.

158 Lince-Deroche N, Leuner R, Chiu C, Teagle A, Kgowedi S. The costs of diagnosing and treating sexually transmitted infections in low- and middle-income countries from 2006 to 2014: An updated systematic review. HE2RO, 2019. https://www.heroza.org/wp-content/uploads/2019/06/Lince-Deroche-et-al.-Systematic-review-of-STI-diagnosis-and-Tx-in-LMIC.-Resbumitted.pdf (accessed Sept 16, 2025).

159 Rinaldi G, Kiadaliri AA, Haghparast-Bidgoli H. Cost effectiveness of HIV and sexual reproductive health interventions targeting sex workers: a systematic review. *Cost Eff Resour Alloc* 2018; **16:** 63.

160 Holmes KK, Bertozzi S, Bloom BR, Jha P. Disease control priorities, 3rd edn (Vol 6). Major infectious diseases. The World Bank, 2017.

161 Ayinde O, Ross JDC, Jackson L. Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study. *PLoS One* 2023; **18:** e0292273.

162 Stover J, Rosen JE, Carvalho MN, et al. The case for investing in the male condom. *PLoS One* 2017; **12:** e0177108.

163 Saweri OPM, Batura N, Al Adawiyah R, et al. Economic evaluation of point-of-care testing and treatment for sexually transmitted and genital infections in pregnancy in low- and middle-income countries: a systematic review. *PLoS One* 2021; **16:** e0253135.

164 Zhang M, Zhang H, Hui X, et al. The cost-effectiveness of syphilis screening in pregnant women: a systematic literature review. *Front Public Health* 2024; **12:** 1268653.

165 Adawiyah RA, Saweri OPM, Boettiger DC, et al. The costs of scaling up HIV and syphilis testing in low- and middle-income countries: a systematic review. *Health Policy Plan* 2021; **36:** 939–54.

166 Khumalo F, Passmore JS, Manhanzva M, et al. Shifting the power: scale-up of access to point-of-care and self-testing for sexually transmitted infections in low-income and middle-income settings. *Curr Opin Infect Dis* 2023; **36:** 49–56.

167 Hsieh K, Melendez JH, Gaydos CA, Wang T-H. Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections. *Lab Chip* 2022; **22:** 476–511.

168 Wi TE, Ndowa FJ, Ferreyra C, et al. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. *J Int AIDS Soc* 2019; **22** (suppl 6)**:** e25343.

169 Kahn JG, Jiwani A, Gomez GB, et al. The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model. *PLoS One* 2014; **9:** e87510.

170 Shepard DS, Halasa-Rappel YA, Rowlands KR, et al. Economic analysis of a new four-panel rapid screening test in antenatal care in Kenya, Rwanda, and Uganda. *BMC Health Serv Res* 2023; **23:** 815.

171 Memirie ST, Tolla MT, Desalegn D, et al. A cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia. *Health Policy Plan* 2019; **34:** 289–97.

172 Burgos JL, Patterson TL, Graff-Zivin JS, et al. Cost-effectiveness of combined sexual and injection risk reduction interventions among female sex workers who inject drugs in two very distinct Mexican border cities. *PLoS One* 2016; **11:** e0147719.

173 Castillo-Laborde C, Gajardo P, Nájera-De Ferrari M, et al. Modelling cost-effectiveness of syphilis detection strategies in prisoners: exploratory exercise in a Chilean male prison. *Cost Eff Resour Alloc* 2021; **19:** 5.

174 Machekera S, Boas P, Temu P, et al. Strategic options for syphilis control in Papua New Guinea- impact and cost-effectiveness projections using the syphilis interventions towards elimination (SITE) model. *Infect Dis Model* 2021; **6:** 584–97.

175 Nhamo D, Mangenah C, Chapwanya G, et al. Feasibility and economic costs of syphilis self-testing to expand test uptake among gay, bisexual and transgender men: results from a randomised controlled trial in Zimbabwe. *Sex Health* 2023; **20:** 514–22.

176 Santos CGD, Sabidó M, Leturiondo AL, Ferreira CO, da Cruz TP, Benzaken AS. Development, validation and testing costs of an in-house real-time PCR assay for the detection of Chlamydia trachomatis. *J Med Microbiol* 2017; **66:** 312–17.

177 Connolly S, Kilembe W, Inambao M, et al. A population-specific optimized GeneXpert pooling algorithm for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* to reduce cost of molecular sexually transmitted infection screening in resource-limited settings. *J Clin Microbiol* 2020; **58:** e00176–20.

178 Marcus R, C P, Gill K, et al. Acceptability, feasibility and cost of point of care testing for sexually transmitted infections among South African adolescents where syndromic management is standard of care. *BMC Health Serv Res* 2023; **23:** 1078.

179 McCartney DJ, Luppi CG, Silva RJC, et al, and the TransOdara Research Group. Anorectal gonorrhoea and chlamydia among transgender women in Brazil: prevalence and assessment of performance and cost of anorectal infection detection and management approaches. *Sex Transm Infect* 2024; **100:** 3–9.

180 Wynn A, Moucheraud C, Martin NK, et al. Bridging the gap between pilot and scale-up: a model of antenatal testing for curable sexually transmitted infections from Botswana. *Sex Transm Dis* 2022; **49:** 59–66.

181 Smith E, Masson L, Passmore JS, Sinanovic E. Cost-effectiveness analysis of different screening and diagnostic strategies for sexually transmitted infections and bacterial vaginosis in women attending primary health care facilities in Cape Town. *Front Public Health* 2023; **11:** 1048091.

182 Slavkovsky R, Callen E, Pecenka C, Mvundura M. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: a systematic review. *Vaccine* 2024; **42:** 1200–10.

183 Tran PT, Riaz M, Chen Z, Truong CB, Diaby V. An umbrella review of the cost effectiveness of human papillomavirus vaccines. *Clin Drug Investig* 2022; **42:** 377–90.

184 Okeah BO, Ridyard CH. Factors influencing the cost-effectiveness outcomes of HPV vaccination and screening interventions in low-to-middle-income countries (LMICs): a systematic review. *Appl Health Econ Health Policy* 2020; **18:** 641–54.

185 Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. *Vaccine* 2013; **31:** 3786–804.

186 Mekuria SF, Timmermans S, Borgfeldt C, Jerkeman M, Johansson P, Linde DS. HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC: a systematic review and meta-analysis. *Syst Rev* 2023; **12:** 103.

187 Malone C, Barnabas RV, Buist DSM, Tiro JA, Winer RL. Cost-effectiveness studies of HPV self-sampling: a systematic review. *Prev Med* 2020; **132:** 105953.

188 Tu H-AT, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. Economic evaluations of hepatitis B vaccination for developing countries. *Expert Rev Vaccines* 2009; **8:** 907–20.

189 Wright CM, Boudarène L, Ha NT, Wu O, Hawkins N. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries. *BMC Public Health* 2018; **18:** 373.

190 Razavi-Shearer D. The economic argument for hepatitis B treatment simplification and expansion. *J Viral Hep* 2024; **31:** 23–26.

191 Toy M, So S, Hutton DW. Hepatitis B cure: modeling the economics of a potential cost of a cure. *Curr Opin HIV AIDS* 2020; **15:** 208–12.

192 Kohler H-P, Behrman JR. Benefits and costs of the population and demography targets for the post-2015 development agenda. Copenhagen Consensus, 2014.

193 Zakiyah N, van Asselt ADI, Roijmans F, Postma MJ. Economic evaluation of family planning interventions in low and middle income countries; a systematic review. *PLoS One* 2016; **11:** e0168447.

194 Schnippel K, Lince-Deroche N, van den Handel T, Molefi S, Bruce S, Firnhaber C. Cost evaluation of reproductive and primary health care mobile service delivery for women in two rural districts in South Africa. *PLoS One* 2015; **10:** e0119236.

195 Omame A, Nnanna CU, Inyama SC. Optimal control and cost-effectiveness analysis of an HPV-*Chlamydia trachomatis* co-infection model. *Acta Biotheor* 2021; **69:** 185–223.

196 Obure CD, Sweeney S, Darsamo V, et al, and the Integra Initiative. The costs of delivering integrated HIV and sexual reproductive health services in limited resource settings. *PLoS One* 2015; **10:** e0124476.

197 Mangenah C, Sibanda EL, Maringwa G, et al. Provider and female client economic costs of integrated sexual and reproductive health and HIV services in Zimbabwe. *PLoS One* 2024; **19:** e0291082.

198 Quirola-Amores P, Espinosa P, Oleas S, Hernandez I, Henriquez AR, Teran E. HIV rapid testing in the general population and the usefulness of PrEP in Ecuador: a cost-utility analysis. *Front Public Health* 2022; **10:** 884313.

199 Chevalier JM, Hansen MA, Coskun E, et al. Cost-effectiveness of intervention combinations towards the elimination of vertical transmission of HIV in limited-resource settings: a mathematical modelling study. *Lancet Glob Health* 2024; **12:** e457–66.

200 Murombedzi C, Chirinda L, Chareka GT, Chirenje ZM, Mgodi NM. Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe. *Front Reprod Health* 2023; **5:** 1279124.

201 AVAC. A plan for accelerating access and introduction of injectable CAB for PrEP. AVAC, 2022. https://avac.org/resource/report/a-plan-for-accelerating-access-and-introduction-of-injectable-cab-for-prep-summary/ (accessed Nov 29, 2024).

202 AVAC. From clinical trial efficacy to public health impact. A plan for accelerating access to injectable lenacapavir for PrEP. AVAC, 2024 https://avac.org/resource/report/from-clinical-trial-efficacy-to-public-health-impact-a-plan-for-accelerating-access-to-injectable-lenacapavir-for-prep/ (accessed Dec 9, 2024).

203 WHO. Implementation of self-care interventions for health and well-being: guidance for health systems. World Health Organization, 2024. https://www.who.int/news-room/fact-sheets/detail/self-care-health-interventions (accessed Nov 29, 2024).

204 Anderson DJ, Bearak JM, Grimstad FW, et al. Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health. *Lancet* 2025; **406:** 2078–88.

205 WHO. WHO recommendations on self-care interventions. World Health Organization, 2020 https://iris.who.int/bitstream/handle/10665/332334/WHO-SRH-20.11-eng.pdf (accessed Dec 9, 2024).

206 Torres-Rueda S, Terris-Prestholt F, Gafos M, et al. Health economics research on non-surgical biomedical HIV prevention: identifying gaps and proposing a way forward. *PharmacoEconomics* 2023; **41:** 787–802.

207 Seninde I, Schutte C, Smith E. Integration of HIV services with primary health care: a comprehensive review of costs and cost-effectiveness. IAS 2024, the 25th International AIDS Conference; July 22–26, 2024.

208 Bulstra CA, Hontelez JAC, Otto M, et al, and the UNAIDS Expert Group on Integration. Integrating HIV services and other health services: a systematic review and meta-analysis. *PLoS Med* 2021; **18:** e1003836.

209 Bartoo AS, Gilmer MA, Tichy EM. Antimicrobial shortages: a global issue impacting infectious diseases. *Clin Infect Dis* 2024; **80:** 249–52.

210 Ong JJ, Fu H, Baggaley RC, et al. Missed opportunities for sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review. *J Int AIDS Soc* 2021; **24:** e25673.

211 UN Population Fund. Annual impact report 2023. UNFPA, 2023. https://www.unfpa.org/sites/default/files/pub-pdf/Web_UNFPA%20Supplies%20Impact%20Report%202023.pdf (accessed Dec 9, 2024).

212 Venter WDF, Gandhi M, Sokhela S, et al. The long wait for long-acting HIV prevention and treatment formulations. *Lancet HIV* 2024; **11:** e711–16.

213 Bekker L-G, Das M, Abdool Karim Q, et al, and the PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. *N Engl J Med* 2024; **391:** 1179–92.

214 Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. *N Engl J Med* 2024; **3:** 1261–76.

215 Allel K, Abou Jaoude GJ, Birungi C, Palmer T, Skordis J, Haghparast-Bidgoli H. Technical efficiency of national HIV/AIDS spending in 78 countries between 2010 and 2018: a data envelopment analysis. *PLOS Glob Public Health* 2022; **2:** e0000463.

Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.